North China Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
North China Pharmaceutical Co Ltd cash flow-to-debt ratio. North China Pharmaceutical Co Ltd (600812) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of CN¥170.24 Million could theoretically repay 0% of its total liabilities (CN¥14.86 Billion) in one year. Check 600812 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of North China Pharmaceutical Co Ltd (1998–2025)
Cash flow-to-debt ratio of North China Pharmaceutical Co Ltd from 1998 to 2025. Historical debt coverage capacity for North China Pharmaceutical Co Ltd across 28 annual periods. Check North China Pharmaceutical Co Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
North China Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (1998–2025)
North China Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 1998 to 2025. Year-by-year debt coverage analysis for North China Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see North China Pharmaceutical Co Ltd cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.08x | CN¥1.18 Billion | CN¥14.51 Billion | ▼ -2.4% |
| 2024 | 0.08x | CN¥1.23 Billion | CN¥14.80 Billion | ▲ +19.1% |
| 2023 | 0.07x | CN¥1.02 Billion | CN¥14.69 Billion | ▲ +4.1% |
| 2022 | 0.07x | CN¥1.00 Billion | CN¥14.99 Billion | ▲ +14.3% |
| 2021 | 0.06x | CN¥1.05 Billion | CN¥17.91 Billion | ▲ +31.6% |
| 2020 | 0.04x | CN¥752.15 Million | CN¥16.88 Billion | ▼ -21.5% |
| 2019 | 0.06x | CN¥732.97 Million | CN¥12.92 Billion | ▼ -9.1% |
| 2018 | 0.06x | CN¥774.33 Million | CN¥12.40 Billion | ▲ +158.0% |
| 2017 | 0.02x | CN¥287.25 Million | CN¥11.87 Billion | ▲ +160.6% |
| 2016 | -0.04x | CN¥-446.53 Million | CN¥11.18 Billion | ▼ -449.6% |
| 2015 | 0.01x | CN¥122.50 Million | CN¥10.73 Billion | ▲ +30.1% |
| 2014 | 0.01x | CN¥90.56 Million | CN¥10.32 Billion | ▲ +167.7% |
| 2013 | -0.01x | CN¥-135.03 Million | CN¥10.41 Billion | ▼ -89.9% |
| 2012 | -0.01x | CN¥-63.92 Million | CN¥9.36 Billion | ▼ -129.9% |
| 2011 | 0.02x | CN¥227.60 Million | CN¥9.95 Billion | ▲ +130.3% |
| 2010 | -0.08x | CN¥-598.35 Million | CN¥7.94 Billion | ▼ -147.8% |
| 2009 | 0.16x | CN¥1.01 Billion | CN¥6.41 Billion | ▼ -22.0% |
| 2008 | 0.20x | CN¥1.09 Billion | CN¥5.37 Billion | ▲ +58.8% |
| 2007 | 0.13x | CN¥664.37 Million | CN¥5.22 Billion | ▲ +19.8% |
| 2006 | 0.11x | CN¥597.12 Million | CN¥5.61 Billion | ▲ +163.2% |
| 2005 | 0.04x | CN¥224.17 Million | CN¥5.55 Billion | ▼ -23.3% |
| 2004 | 0.05x | CN¥310.39 Million | CN¥5.89 Billion | ▼ -59.1% |
| 2003 | 0.13x | CN¥580.32 Million | CN¥4.51 Billion | ▼ -25.2% |
| 2002 | 0.17x | CN¥738.50 Million | CN¥4.29 Billion | ▲ +117.1% |
| 2001 | 0.08x | CN¥367.28 Million | CN¥4.63 Billion | ▲ +94.0% |
| 2000 | 0.04x | CN¥133.49 Million | CN¥3.27 Billion | ▲ +131.7% |
| 1999 | -0.13x | CN¥-373.62 Million | CN¥2.90 Billion | ▲ +20.8% |
| 1998 | -0.16x | CN¥-326.74 Million | CN¥2.01 Billion | — |